UNII RS7A450LGA

ANHYDROUS TRISODIUM CITRATE

Unique Ingredient Identifier RS7A450LGA is listed as a ingredient substance
UniiRS7A450LGA
Preferred Substance NameANHYDROUS TRISODIUM CITRATE
Rn68-04-2
Ec200-675-3
NcitC66542
Rxcui1310549
Pubchem6224
Molecular FormulaC6H5O7.3Na
InchikeyHRXKRNGNAMMEHJ-UHFFFAOYSA-K
Smiles[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
Unii TypeINGREDIENT SUBSTANCE
RN68-04-2
EC200-675-3
NCITC66542
RXCUI1310549
PUBCHEM6224
MFC6H5O7.3Na
INCHI KEYHRXKRNGNAMMEHJ-UHFFFAOYSA-K
SMILES[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O

Alternate Names

Dosage Forms

UNII RS7A450LGA ANHYDROUS TRISODIUM CITRATE is commonly included in medications in the following forms.

RouteDosage FormPotency
IM - IVINJECTION16 %
INHALATIONSUSPENSION0.9 mg/2mL
INTRA-ARTERIALINJECTION NA
INTRA-ARTICULARINJECTION1 %
INTRABURSALINJECTION1 %
INTRALESIONALINJECTION0.96 %W/V
INTRAMUSCULARINJECTION0.96 %W/V
INTRAVENOUSINJECTION0.96 %W/V
INTRAVENOUSPOWDER, FOR INJECTION SOLUTION6.99 %
IV(INFUSION)CONCENTRATE2.4 %
IV(INFUSION)INJECTION16 %
NASALSPRAY1.27 %
NASALSPRAY, METERED0.001 %
OPHTHALMICSOLUTION NA
ORALFOR SUSPENSION9 MG/5ML
ORALGRANULE NA
ORALGRANULE, EFFERVESCENT NA
ORALLIQUID,EXTENDED RELEASE3.9 MG/ML
ORALPOWDER, FOR ORAL SUSPENSION19.31 MG/5ML
ORALPOWDER, FOR RECONSTITUTION7.5 MG/5ML
ORALPOWDER, FOR SOLUTION48 MG/5ML
ORALPOWDER, FOR SUSPENSION66.7 MG/5ML
ORALSOLUTION30 MG/5ML
ORALSUSPENSION7.5 MG/5ML
ORALSYRUP7.95 MG/5ML
ORALTABLET28 MG
ORALTABLET (IMMED./COMP. RELEASE), UNCOATED, EFFERVESC935 MG
ORALTABLET, DELAYED ACTION, ENTERIC COATED15 MG
SOFT TISSUEINJECTION0.96 %W/V
SUBLINGUALFILM1.34 MG
SUBLINGUALTABLET2.68 MG
TOPICALCREAM0.05 %W/W
TOPICALCREAM, EMULSION, SUSTAINED RELEASE0.12 %W/W
TOPICALEMULSION, CREAM0.28 %W/W
TOPICALLOTION0.075 %W/W

© 2021 FDA.report
This site is not affiliated with or endorsed by the FDA.